HIV infection and chronic drinking have a synergistic, damaging effect on the brain

July 23, 2009

More than half of clinic patients infected with the human immunodeficiency virus (HIV) report they also drink heavily. While highly active antiretroviral therapy has helped to reduce HIV-related cognitive and motor deficits, neuropsychological deficits may continue and even be exacerbated by alcohol. A study of memory deficits has found that HIV infection and chronic alcoholism have synergistic, damaging effects on brain function.

Results will be published in the October issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.

"It has been consistently documented that chronic heavy drinking results in cognitive and motor deficits, particularly impairments in component processes of executive functions, memory, visuospatial abilities, and speed of cognitive processing and motor movements," said Edith V. Sullivan, professor in the department of psychiatry and behavioral sciences at Stanford University School of Medicine and corresponding author for the study. "Chronic heavy drinking co-occurring with is highly prevalent, and the separate and combined untoward effects on the brain and its processes can be significant and disruptive of activities of daily living."

This prevalence exists despite considerable educational and prevention programs regarding both HIV and alcoholism, added Sara Jo Nixon, a professor in the department of psychiatry at the University of Florida. "Furthermore, their comorbidity constitutes an even greater health concern with implications for treatment adherence, work and interpersonal skill maintenance."

Sullivan and her colleagues examined working and episodic memory in four groups (n=164) - 40 individuals with HIV (28 men, 12 women), 38 with chronic alcoholism (24 men, 14 women), 47 with both HIV and chronic alcoholism (38 men; 9 women), and 39 "normal" controls (22 men, 17 women) - at baseline and then again at a one-year follow-up. Measures included accuracy scores, response times, and rate of information processing.

"Individuals who are both positive for HIV and have a history of chronic heavy drinking are at greater risk than individuals with only one of these conditions to have trouble learning new information," said Sullivan. "This difficulty in new learning can affect an individual's ability to use information important to the successful completion of personal and work-related activities."

"Too frequently, when widespread deficits are associated with disease, the need to disentangle underlying interacting processes is overlooked," said Nixon. "Specifically, Sullivan and her colleagues' ability to identify a particular component of memory, 'episodic,' as being impaired, while another, 'working,' is spared supports the continued to need construct studies which provide explicit contrasts among subprocesses which may be inappropriately grouped under a broad superordinate category." In other words, she said, specific damages were "cloaked" by overall damage prior to this study.

"Immediate episodic memory is dependent on intact medial temporal lobe systems that have been shown to be affected in both HIV infection and chronic alcoholism," explained Sullivan, "whereas working memory is primarily associated with more frontally based systems that may not be as severely effected at this moderate stage of disease. Results showed that individuals were able to retain information over time, which suggests that retrieval of information was intact, whereas lower scores on immediate memory suggested that difficulties were associated with ability to learn, or encode, information."

"The immediate real-world and clinical impact of this study is considerable," observed Nixon. "The data suggest that specific interventions for enhancing the process of encoding or learning new information, such as prescription regimens, should be employed to enhance treatment outcomes as well as work and interpersonal situations. If individuals are aware and engage in 'encoding-rich' strategies, overall quality of life and adaptation may be enhanced."

Nixon also noted that questions have been raised regarding the impact of anti-retrovirals on the brain. "While these medications can effectively control obvious markers of , indirect measures on neurocognitive function are less clear," she said. "There is a need to examine this behavioral/biochemical dissociation."

Source: Alcoholism: Clinical & Experimental Research

Related Stories

Recommended for you

Study suggests a way to stop HIV in its tracks

December 1, 2017
When HIV-1 infects an immune cell, the virus travels to the nucleus so quickly there's not enough time to set off the cell's alarm system.

Discovery puts the brakes on HIV's ability to infect

November 30, 2017
Viewed with a microscope, the virus faintly resembles a pineapple—the universal symbol of welcome. But HIV, the virus that causes AIDS, is anything but that. It has claimed the lives of more than 35 million people so far.

Rising levels of HIV drug resistance

November 30, 2017
HIV drug resistance is approaching and exceeding 10% in people living with HIV who are about to initiate or reinitiate first-line antiretroviral therapy, according to the largest meta-analysis to date on HIV drug resistance, ...

Male circumcision and antiviral drugs appear to sharply reduce HIV infection rate

November 29, 2017
A steep drop in the local incidence of new HIV infections accompanied the rollout of a U.S.-funded anti-HIV program in a large East-African population, according to a study led by researchers at Johns Hopkins Bloomberg School ...

Combination HIV prevention reduces new infections by 42 percent in Ugandan district

November 29, 2017
A study published today in the New England Journal of Medicine provides real-world evidence that implementing a combination of proven HIV prevention measures across communities can substantially reduce new HIV infections ...

Research on HIV viral load urges updates to WHO therapy guidelines

November 24, 2017
A large cohort study in South Africa has revealed that that low-level viraemia (LLV) in HIV-positive patients who are receiving antiretroviral treatment (ART) is an important risk factor for treatment failure.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.